HMB Supplement Study for ALS
Part of Brain & nervous system, Hormones & metabolism clinical trials.
This pilot trial tests whether a dietary supplement called HMB (beta-hydroxy-beta-methylbutyrate) can help lower a protein called IGFBP7 that may be linked to ALS progression. If it works, this approach might slow down muscle weakness in people with ALS.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with ALS (amyotrophic lateral sclerosis, also called Lou Gehrig's disease)
- You are at least 18 years old
- You can read, write, and understand English
- You are able and willing to give informed consent to participate
- You have not taken HMB supplements in the past 30 days
- You are not currently in another clinical trial, or stopped participation more than 30 days ago
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a transplant of healthy gut bacteria (called a microbiome transplant) can slow down ALS in people whose disease is progressing rapidly. It aims to see if changing the gut environment can help with symptoms and quality of life.
This study tests an investigational drug called NB-4746 for people with ALS. The goal is to see if it can slow the progression of the disease. It is for people diagnosed within the last couple of years who are still able to eat and breathe on their own.
This trial tests a new treatment made from stem cells (called XS228CN) injected into the spine. It is primarily a safety study, but doctors will also watch for any signs the treatment may slow ALS progression.
This Phase 2 trial tests a treatment meant to improve “energy production” in people with ALS. It aims to see whether increasing mitochondrial (cell energy) capacity can help ALS symptoms or progression.
This trial tests whether adding two supplements (EH-301 and N-acetylcysteine) to the standard ALS medicine Riluzole can help slow the disease. It is for people diagnosed with ALS within the last 18 months who still have good breathing and daily function.
This trial tests whether FB1006 is safe and works better than usual care for treating amyotrophic lateral sclerosis (ALS). It focuses on people with relatively early ALS and good breathing function.
Hear when a new Amyotrophic Lateral Sclerosis ALS trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.